PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00820794
A Study to Compare Two Ways of Completing Pain and Sleep Questions and to Evaluate a New Daily Questionaire for Assessing Fatigue in Fibromyalgia Patients
Not Applicable
Completed
- Conditions
- Fibromyalgia
- Interventions
- Other: Personal Digital Assisstant (PDA)Other: Interactive Voice Response System (IVRS)
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2010-02-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 185
- Registration Number
- NCT00819624
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Spokane, Washington, United States
Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit
Phase 4
Completed
- Conditions
- Smoking CessationInsurance Coverage
- Interventions
- Other: Full Smoking Cessation Treatment Coverage (100%)Other: No Smoking Cessation Treatment Coverage (0%)
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2012-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1380
- Registration Number
- NCT00818207
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 119
- Registration Number
- NCT00818441
- Locations
- ๐บ๐ธ
St. John's Hospital,, Springfield, Missouri, United States
๐บ๐ธStony Brook University Medical Center - Cancer Center, Stony Brook, New York, United States
๐บ๐ธSeattle Cancer Care Alliance, Seattle, Washington, United States
Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis
- First Posted Date
- 2008-12-31
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00815906
- Locations
- ๐ฏ๐ต
Pfizer Investigational Site, Tokyo, Japan
A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031
Phase 1
Completed
- Conditions
- Prostatic HyperplasiaUrinary Bladder, OveractiveErectile Dysfunction
- Interventions
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2008-12-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT00814736
- Locations
- ๐ธ๐ฌ
Pfizer Investigational Site, Singapore, Singapore
A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis
- First Posted Date
- 2008-12-24
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 611
- Registration Number
- NCT00814307
- Locations
- ๐บ๐ฆ
Pfizer Investigational Site, Vinnitsa, Ukraine
A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2009-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 78
- Registration Number
- NCT00812825
- Locations
- ๐ง๐ช
Pfizer Investigational Site, Bruxelles, Belgium
A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis
Phase 2
Terminated
- Conditions
- Ankylosing Spondylitis
- Interventions
- Drug: ARRY-371797, p38 inhibitor; oralDrug: Placebo; oral
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00811499
- Locations
- ๐บ๐ธ
Westroads Medical Group, Omaha, Nebraska, United States
๐บ๐ธCedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
Safety And Efficacy Of Rifabutin In HIV Patients
Completed
- Conditions
- Non-tuberculous Mycobacterial DiseasesTuberculosisInhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
- Interventions
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT00810446
ยฉ Copyright 2025. All Rights Reserved by MedPath